The main reason for this week's decline is that Moderna lowered its 2025 full-year revenue guidance, and by a wide margin.

CDC officials say medical professionals are seeing more patients whose illness cannot be traced back to an infected animal or ...

At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...

The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...

Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.

Moderna now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most of which will come in the second half ...

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...

Shares of Moderna plunged 20% Monday after the vaccine maker slashed its forecast of full-year 2025 revenue, as sales of its ...

Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine has performed poorly. Read my ...

Shares of Moderna tumbled Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year ...

Moderna/Merck partnership and its potential in personalised cancer therapies are good opportunities for long-term investors.

Moderna shares will likely remain under scrutiny after plunging nearly 17% Monday as the embattled drug maker slashed its ...